- Baxter signs definitive agreement to sell its biopharmaceutical solutions business to Advent International and Warburg Pincus for $4.25 billionBaxter
- Baxter sells biopharma solutions arm for $4.25 billionThe Wall Street Journal
- Baxter negotiates $4.25 billion sale of biopharma solutions segmentFierceBiotech
- Baxter stock to sell BioPharma Solutions business for $4 billion in cashLooking for Alpha
- Advent and Warburg Pincus Lead Multi-Billion Bid for Baxter’s Biopharmaceutical SolutionsYahoo finance
- See full coverage on Google News